Ocaliva OK'd; Will NASH Success, Acquisition Be Next For Intercept?
As expected, Intercept Pharmaceuticals Inc. was granted an accelerated approval for Ocaliva (obeticholic acid) as a treatment for primary biliary cholangitis. But the drug's potential in the much more lucrative indication of nonalcoholic steatohepatitis may be what piques the interests of larger pharmaceutical companies for a possible acquisition of the New York-based biotech.
You may also be interested in...
The numerous different targets of investigational drugs for the treatment of NASH suggest the jury is still out on which mechanism of action is most likely to prove effective against the condition. Ireland’s Afimmune is the latest company wanting to advance an investigational drug for the disorder into late-stage clinical studies.
Shire's Danish chief executive says completing the Baxalta merger will greatly boost the group's exposure to longer acting orphan drugs, bring critical mass and de-risk its current asset mix with new portfolio products; a view widely shared by investors and analysts.
After the FDA's glowing review on paper and even more so at the meeting of the agency's Gastrointestinal Drugs Advisory Committee, it was highly likely the panel would back a speedy approval of Intercept Pharmaceuticals Inc.'s Ocaliva (obeticholic acid) as a treatment for primary biliary cholangitis (PBC), a rare and potentially fatal liver disease.